Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus temozolomide for recurrent or refractory high-grade glioma
ACTRN12611000418976Phase 2Completed
- Sponsor
- HeCOG
- Start
- Jan 2009
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib and temozolomide in glioma, glioblastoma (GBM) and anaplastic astrocytoma (AA) (4 arms), sponsored by HeCOG. Primary endpoints: Maximum tolerated dose and recommended phase II dose, Safety and tolerability and 1 more. Started Jan 2009; status: completed.
02
Drugs
lapatinibtemozolomide
03
Conditions
gliomaglioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on ACTRN12611000418976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000418976.